XKRX
003220
Market cap130mUSD
Oct 08, Last price
8,190.00KRW
1D
-0.73%
1Q
2.38%
Jan 2017
-48.15%
Name
Daewon Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1958 and headquartered in Seoul, South Korea, Daewon Pharmaceutical Co., Ltd. is a well-regarded pharmaceutical enterprise specializing in the development, manufacturing, and distribution of a comprehensive range of medications and medical supplies within the South Korean market. Its extensive product portfolio targets diverse therapeutic fields, encompassing cardiovascular, respiratory, anti-infective, oncology, and neuropsychiatric conditions. Key offerings include Oramin-F Soft Cap, a notable multivitamin; Pelubi Tablet, an NSAID specifically formulated for pain management; Freefol-MCT Inj., a microemulsion propofol designed to prevent exogenous bacterial infections; Megex-I Susp, a medication that supports the nutritional needs of cancer patients experiencing subalimentation; Trigel Susp, an effective treatment for gastritis and duodenal ulcers; and Renamezin Cap, a spherical carbonaceous adsorbent for managing chronic kidney disease. Furthermore, Daewon Pharmaceutical extends its global footprint by exporting its products to approximately 45 countries, predominantly across Asia, Central and South America, and the Middle East.
Key people
Su Gap Kim
Assistant Managing Director · since 2023
Sang Hui Lee
Assistant Managing Director · since 2024
Gil Ho Lee
Assistant Managing Director · since 2024
Jun Hyeok Lee
Assistant Managing Director
Ah Ram Lee
Assistant Managing Director · since 2024
Seon Wu Lee
Assistant Managing Director · since 2023
Jeong Hui Lee
Assistant Managing Director · since 2024
Yeong Jun Park
Assistant Managing Director · since 2024
Cheol Hui Won
Assistant Managing Director · since 2022
Geun Man Yoo
Assistant Managing Director · since 2022
Seung Yeol Baek
Co-Chief Executive Officer, Vice Chairman, Director · since 2018
Ju Yeon Cho
Non-Executive Independent Director · since 2025
Dong Hui Lee
Non-Executive Independent Director · since 2024
Yong Ju Park
Non-Executive Independent Director
Yeo Won Son
Non-Executive Independent Director
IPO date
Dec 15, 1999
Employees
Domiciled in
KR
Incorporated in
KR
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||